Print

Active Biotech to Present at the JP Morgan 30th Annual Healthcare Conference

2012-01-04

Lund, Sweden, January 4, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the JP Morgan 30th Annual Healthcare Conference held
January 8-12, 2012 in San Francisco, US. During the presentation, an update regarding Active Biotech's development programs will be provided.

The presentation will include the laquinimod MS project, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical Industries Ltd, the Phase III prostate cancer project TASQ in co-development with Ipsen, as well as ANYARA, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, the project 57-57 and the pre-clinical ISI project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to - www.activebiotech.com.

The presentation will take place on January 12, at 8:00 am PST (Pacific Standard Time) / 17.00 Central European Time.

About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for Systemic Sclerosis as well as RhuDexTM for RA. Please visit www.activebiotech.com for more information.

Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CET on January 4, 2012.

Contacts:
Active Biotech AB
Hans Kolam, CFO
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00


pdfActive Biotech to Present at JP Morgan



Back